Member Info for Yorkshirepragma

Vera causa….gla

RM…You can write to complain to their CEO vi their comms team.
I have……many see this a fruitless…I prefer to consider it representing the right position, as you defer to.
Becomes more galling when you read Jupiter’s nonsense about sustainability values and ethics….bizarre to say the least.
Regards

Additional background..

https://www.reuters.com/article/us-astrazeneca-cancer-daiichi-sankyo-idUSKCN24S0HP

4% increase attributed to above an antibody drug conjugate effective within breast cancer sphere, and market $3bn peak.
Sounds familiar?
GLA

That’s good….& visitors to Thorpe arch yet?
Watching closely….

Energy shares.. ditto, particularly when for M&A $1tri reportedly available in 2022 , and notably recent years have seemingly not had too many broad range targets .
https://www.biopharmadive.com/news/biotech-pharma-deals-merger-acquisitions-tracker/604262/
Patience is a virtue ,they say.

W, please read the note old chap…

Quercus….ditto, quite a ‘load of old nonsense’ as my grandad used to say…
They need to be held to account . Jupiter annual perhaps ,a suitable occasion, should no reply be forthcoming.

Tim, I certainly will. Also sent to their new Head of Sustainability…what corporate nonsense in the context of what we’re seeing here.
… ,so may get out the old press contacts book.

…..to Jupiter corporate communications . Email on site.
Feel free to ask also..
On 18 Feb

?
Please forward to Mr Formica for attention/ consideration.
To: andrew.formica@jupiter-group.co.uk
Subject: Jupiter shorting against a Novel Cancer drug company ( Avacta)

?
?Dear Mr Formica

I wonder whether you are personally aware of the above?

In this instance 1% + held, and so disrupting a companies position ,which is inevitably harmed by such action.

As your company engages in this activity ,their medical scientists undertake potentially ‘step changing ‘ treatments with the help of brave stage cancer patients participating in studies using their new technology in several UK hospitals.

https://avacta.com/avacta-announces-dose-escalation-in-the-phase-i-clinical-study-of-ava6000-pro-doxorubicin/

I’m appalled, and this is something I’d appreciate your view on ,set against Jupiter’s declared sustainable ethics approach.

This is certainly questionable behaviour that one expects from a modern investment vehicle.

I look forward to your considered comments as a responsible CEO.

Yours Sincerely

Well you might ever know... let’s see...

Quitea bizarre ethical contrast that eg Jupiter shorters push this position , to the companies detriment, whilst at the same time several brave patients participate in AVA trails .

I sincerely hope you’re wrong…a great UK business could come of Avacta…with great tech. @ sig. value to all.
Right now a sitting duck… as it’s business definition clarifys , and demonstrates potential.
GLA

Marvellous progress…..opens door to more caring treatment for millions.

Comment ….I’ve never known a CEO go to one of these without a decent ‘story’
On y va…

https://www.biopharmadive.com/news/biotech-pharma-deal-questions-trends-2022/617039/

A great example of Affimer tech value….

And a good team, comes highly recommended….
I’d say shorters shock coming!

https://www.biopharmadive.com/news/biotech-pharma-deal-questions-trends-2022/617039/

Large pharma has no choice but to go with external aquisitions…..
GLA

M&A delayed action , suggests “ catch up “ likely.
With Av potential for share of £bnblevel markets ?
GLA

https://www.biopharmadive.com/news/biotech-pharma-deal-questions-trends-2022/617039/